These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24156566)

  • 1. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies.
    D'Urzo A; Kerwin E; Overend T; D'Andrea P; Chen H; Goyal P
    Curr Med Res Opin; 2014 Mar; 30(3):493-508. PubMed ID: 24156566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
    Chapman KR; Beeh KM; Beier J; Bateman ED; D'Urzo A; Nutbrown R; Henley M; Chen H; Overend T; D'Andrea P
    BMC Pulm Med; 2014 Jan; 14():4. PubMed ID: 24438744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.
    D'Urzo A; Ferguson GT; van Noord JA; Hirata K; Martin C; Horton R; Lu Y; Banerji D; Overend T
    Respir Res; 2011 Dec; 12(1):156. PubMed ID: 22151296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
    Carter NJ
    Drugs; 2013 May; 73(7):741-53. PubMed ID: 23677802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.
    Bateman ED; Ferguson GT; Barnes N; Gallagher N; Green Y; Henley M; Banerji D
    Eur Respir J; 2013 Dec; 42(6):1484-94. PubMed ID: 23722616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
    Watz H; Mailänder C; May C; Baier M; Kirsten AM
    Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
    Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
    BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
    Kerwin E; Hébert J; Gallagher N; Martin C; Overend T; Alagappan VK; Lu Y; Banerji D
    Eur Respir J; 2012 Nov; 40(5):1106-14. PubMed ID: 23060624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.
    D'Urzo A; Bader G; Shen S; Goyal P; Altman P
    NPJ Prim Care Respir Med; 2018 May; 28(1):18. PubMed ID: 29795478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
    Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
    Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
    Mahler DA; Decramer M; D'Urzo A; Worth H; White T; Alagappan VK; Chen H; Gallagher N; Kulich K; Banerji D
    Eur Respir J; 2014 Jun; 43(6):1599-609. PubMed ID: 24176997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.